<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01851499</url>
  </required_header>
  <id_info>
    <org_study_id>Normast-2013</org_study_id>
    <nct_id>NCT01851499</nct_id>
  </id_info>
  <brief_title>Ultramicronized PEA (Normast) in Spinal Cord Injury Neuropathic Pain</brief_title>
  <official_title>Ultramicronized PEA (Normast) in Spinal Cord Injury Neuropathic Pain: a Randomized, Double-blind, Placebo-controlled, Parallel, Multi-center Study</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Danish Pain Research Center</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Spinal Cord Injury Centre of Western Denmark</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Glostrup University Hospital, Copenhagen</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Epitech Group SRL, Italy</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Danish Pain Research Center</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Randomized, double-blinded, placebo-controlled, parallel group study of ultramicronized PEA
      (Normast)600 mg x 2 daily or corresponding placebo with a week of baseline period followed by
      1 x 12 weeks treatment period.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Study design: Randomized, double-blinded, placebo-controlled, parallel, multi-center study of
      ultramicronized PEA (Normast)with a week of baseline period followed by 1 x 12 weeks
      treatment period.

      Methodology: Given Normast 600mg x 2 daily or corresponding placebo and kept on that dose for
      12 weeks.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>May 2013</start_date>
  <completion_date type="Actual">October 2015</completion_date>
  <primary_completion_date type="Actual">May 2015</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Double (Participant, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Change in mean pain intensity on a 0-10 numerical rating scale from baseline week to last week of treatment</measure>
    <time_frame>12 weeks</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Spasticity/spasms and sleep disturbance, change in mean score from baseline to last week of treatment</measure>
    <time_frame>12 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Modified Tardieu and clonus over ankle joints</measure>
    <time_frame>12 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Spasticity and spasms on a 0-10 NRS</measure>
    <time_frame>12 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Health related quality of life S-TOPS</measure>
    <time_frame>12 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Global Impression of Change</measure>
    <time_frame>12 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Pain relief of overall pain and at-and below level pain</measure>
    <time_frame>12 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>allodynia(touch and cold)</measure>
    <time_frame>12 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Pain symptoms evaluated by NPSI</measure>
    <time_frame>12 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>pain impact on activities, sleep and mood</measure>
    <time_frame>12 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>effect on unpleasantness</measure>
    <time_frame>12 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>escape medication</measure>
    <time_frame>12 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Insomnia Severity Index</measure>
    <time_frame>12 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>anxiety(GAD-10)</measure>
    <time_frame>12 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>depression(MDI)</measure>
    <time_frame>12 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>NNT for 33% and 50% pain reduction</measure>
    <time_frame>12 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Combined spasticity and pain score (CPSS)</measure>
    <time_frame>12 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Numbers of responders (33% pain reduction) in those with and without allodynia/hyperalgesia and those with different pain symptoms (NPSI)</measure>
    <time_frame>12 weeks</time_frame>
  </secondary_outcome>
  <other_outcome>
    <measure>Blindness is assessed by asking the patients and treating physician which treatment they believed they recieved and the reason for this</measure>
    <time_frame>12 weeks</time_frame>
  </other_outcome>
  <other_outcome>
    <measure>Number of patients with adverse events and number, type and severity of adverse events.</measure>
    <time_frame>12 weeks</time_frame>
    <description>Adverse events are assessed using open-ended questions both during and after treatment period.
SAE reporting will be performed according to GCP and regulatory requirements.</description>
  </other_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">73</enrollment>
  <condition>Neuropathic Pain</condition>
  <condition>Spinal Cord Injury</condition>
  <arm_group>
    <arm_group_label>Ultramicronized PEA (Normast)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Normast is ultramicronized Palmitoylethanolamide (PEA) classified as &quot;Dietary foods for special medical purposes&quot;.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Microgranules</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Same as Normast, without active component.</description>
  </arm_group>
  <intervention>
    <intervention_type>Dietary Supplement</intervention_type>
    <intervention_name>Ultramicronized PEA (Normast)</intervention_name>
    <description>600 mg</description>
    <arm_group_label>Ultramicronized PEA (Normast)</arm_group_label>
    <arm_group_label>Microgranules</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Patients aged 18 years or more with at- and/or below-level neuropathic pain for at
             least 3 months due to trauma or disease of the spinal cord or cauda equina (of at
             least 6 months old) with a mean pain intensity from 4 to 9 on a 0-10 point numeric
             rating scale (NRS) during a one-week baseline period will be eligible for the study

        Exclusion Criteria:

          -  known concomitant severe cerebral damage, terminal illness, planned surgery, pregnancy
             or lactation, alcohol or substance abuse, hypersensitivity to PEA or carrier, and
             psychiatric disease except depression.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Sven R. Andresen, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Spinal Cord Injury Centre of Western Denmark</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Department of Spinal Cord Injuries</name>
      <address>
        <city>Hornbaek</city>
        <zip>3100</zip>
        <country>Denmark</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Spinal Cord Injury Centre of Western Denmark</name>
      <address>
        <city>Viborg</city>
        <zip>8800</zip>
        <country>Denmark</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Denmark</country>
  </location_countries>
  <verification_date>October 2015</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>May 8, 2013</study_first_submitted>
  <study_first_submitted_qc>May 9, 2013</study_first_submitted_qc>
  <study_first_posted type="Estimate">May 10, 2013</study_first_posted>
  <last_update_submitted>October 19, 2015</last_update_submitted>
  <last_update_submitted_qc>October 19, 2015</last_update_submitted_qc>
  <last_update_posted type="Estimate">October 20, 2015</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Neuropathic pain following spinal cord injury</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Wounds and Injuries</mesh_term>
    <mesh_term>Spinal Cord Injuries</mesh_term>
    <mesh_term>Neuralgia</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

